Renodapt S Tablet (Mycophenolate Sodium) | Used to Help Prevent Organ Transplant Rejection

Precaution

Renodapt S Tablet should be used under the supervision of a healthcare professional experienced in immunosuppressive treatment. Because mycophenolate sodium suppresses immune system activity, it can increase susceptibility to infections and may require regular medical monitoring.

• Infections: The medicine can increase the risk of bacterial, viral, fungal, and other infections. Report persistent fever, unusual weakness, or other signs of infection to a healthcare professional.
• Pregnancy: Mycophenolate sodium is associated with an increased risk of pregnancy loss and birth defects. Patients who may become pregnant should discuss pregnancy prevention and planning with their healthcare professional before and during treatment.
• Blood-cell changes: Treatment may cause low blood-cell counts, including anemia or neutropenia. Regular blood tests may be recommended.
• Cancer risk: Long-term immunosuppression can increase the risk of lymphoma and certain other cancers, particularly skin cancers. Limiting excessive exposure to sunlight and UV radiation is advised.
• Gastrointestinal problems: Use caution if there is a history of digestive-system disease. Serious gastrointestinal bleeding, ulcers, or perforation can occur.
• Vaccinations: Live attenuated vaccines should generally be avoided during treatment unless specifically advised by a healthcare professional.
• Allergic reactions: Do not use the medicine if there is a known hypersensitivity to mycophenolate sodium, mycophenolic acid, mycophenolate mofetil, or its ingredients.
• Other medicines: Inform the healthcare professional about all prescription medicines, over-the-counter medicines, vitamins, and supplements before starting treatment.
• Do not stop suddenly: Do not reduce the dose or discontinue Renodapt S Tablet without medical advice, as changes in immunosuppressive treatment may affect transplant management.

Regular follow-up and laboratory monitoring may be required during treatment to assess blood-cell counts and overall response to therapy.

Usage

Renodapt S Tablet should be taken exactly as prescribed by a healthcare professional. It is generally taken on an empty stomach, approximately one hour before or two hours after food, unless otherwise directed.

Swallow the tablet whole with water. Do not crush, chew, or break the tablet unless specifically instructed.

Take the medicine at the same time each day when possible. If a dose is missed, follow the instructions provided by the healthcare professional rather than taking an extra dose.

Do not stop treatment or change the dose without medical advice, even if you feel well.

Uses

Renodapt S Tablet is primarily used as part of an immunosuppressive treatment regimen to help prevent organ rejection after transplantation.

It may be used in patients who have received certain solid-organ transplants, such as:

• Kidney transplant
• Heart transplant
• Liver transplant, when prescribed as part of an appropriate immunosuppressive regimen

The exact treatment combination and duration are determined by the transplant specialist based on the patient's medical condition.

Side Effects

Possible side effects of mycophenolate sodium may include:

Contact a healthcare professional if side effects are persistent, severe, or unusual. Seek urgent medical attention for symptoms such as difficulty breathing, severe allergic reactions, significant bleeding, persistent fever, or severe abdominal pain.

FAQs

1. What is Renodapt S Tablet used for?
Renodapt S Tablet contains mycophenolate sodium and is used as part of immunosuppressive therapy to help prevent organ rejection following transplantation.

2. How does Renodapt S Tablet work?
It reduces the activity of certain immune cells, helping decrease the immune response that can contribute to organ rejection.

3. Can Renodapt S Tablet be stopped suddenly?
Do not stop the medicine without medical advice. Interrupting immunosuppressive treatment can increase the risk of organ rejection.

4. Should Renodapt S Tablet be taken with food?
It is generally taken on an empty stomach, about one hour before or two hours after food. Follow the specific instructions provided by the healthcare professional.

5. Can Renodapt S Tablet increase the risk of infections?
Yes. Because it suppresses immune system activity, it can increase susceptibility to certain infections.

6. Does Renodapt S Tablet require regular blood tests?
Regular blood tests may be recommended to monitor blood cell counts, kidney function, and other relevant parameters during treatment.

7. Can Renodapt S Tablet be used during pregnancy?
Mycophenolate medicines can cause serious harm to an unborn baby. Anyone who is pregnant, planning pregnancy, or may become pregnant should discuss treatment and pregnancy-prevention requirements with a healthcare professional.

8. What should I do if I miss a dose?
Follow the missed-dose instructions provided by your healthcare professional. Do not take an extra dose unless specifically instructed.

9. Can I receive vaccines while taking Renodapt S Tablet?
Some vaccines, especially live vaccines, may not be appropriate during immunosuppressive treatment. Consult a healthcare professional before receiving any vaccine.

10. Is Renodapt S Tablet used alone?
It is commonly used as part of a combination immunosuppressive regimen after transplantation. The treatment plan is determined by the transplant specialist.

Interaction

Renodapt S Tablet (Mycophenolate Sodium) can interact with certain medicines and products, which may change the amount of mycophenolic acid in the body or affect treatment response. Patients should inform their healthcare professional about all prescription medicines, over-the-counter products, vitamins, and supplements they are taking.

Antacids containing magnesium or aluminum hydroxide may decrease the concentration of mycophenolic acid. Their use together with mycophenolate sodium should be discussed with a healthcare professional.

Azathioprine may interact with mycophenolate sodium because both medicines affect purine metabolism. Concomitant use is generally not recommended unless specifically directed by a specialist.

Cholestyramine and other bile acid sequestrants can reduce the absorption or concentration of mycophenolic acid and may decrease its exposure in the body. Oral activated charcoal and other products that interfere with enterohepatic recirculation may have a similar effect.

Sevelamer and certain phosphate binders may decrease mycophenolic acid concentrations. Their use should be reviewed by the treating healthcare professional.

Cyclosporine can reduce exposure to mycophenolic acid. Particular caution may be needed when changing between cyclosporine and other immunosuppressive medicines.

Norfloxacin with metronidazole may reduce mycophenolic acid concentrations. This combination should be discussed with the treating specialist.

Rifampin may decrease mycophenolic acid concentrations. Concomitant use should generally be avoided unless the potential benefit outweighs the possible risk.

Hormonal contraceptives may have reduced effectiveness during treatment with mycophenolate sodium. Additional contraceptive measures may therefore be recommended.

Acyclovir, valacyclovir, ganciclovir, and valganciclovir may interact through renal tubular secretion and can affect drug or metabolite concentrations. Blood cell counts may require monitoring when these medicines are used together.

Because Renodapt S Tablet is an immunosuppressive medicine, interactions should be reviewed carefully before starting, stopping, or changing any other medicine. Do not make medication changes without guidance from the healthcare professional managing the treatment.